JPY 657.0
(-2.95%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -11.12 Billion JPY | -45.95% |
2022 | -7.62 Billion JPY | -35.4% |
2021 | -5.63 Billion JPY | -28.38% |
2020 | -4.38 Billion JPY | -133.83% |
2019 | -1.87 Billion JPY | -412.52% |
2018 | -366.08 Million JPY | 36.28% |
2017 | -574.51 Million JPY | -505.06% |
2016 | 141.83 Million JPY | 113.07% |
2015 | -1.08 Billion JPY | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 Q1 | -6.48 Billion JPY | 15.0% |
2023 FY | -11.12 Billion JPY | -45.95% |
2023 Q2 | -7.3 Billion JPY | -12.65% |
2023 Q4 | -11.12 Billion JPY | -43.43% |
2023 Q3 | -7.75 Billion JPY | -6.27% |
2022 Q3 | -6.58 Billion JPY | -17.71% |
2022 Q2 | -5.59 Billion JPY | -8.0% |
2022 Q1 | -5.18 Billion JPY | 8.02% |
2022 FY | -7.62 Billion JPY | -35.4% |
2022 Q4 | -7.62 Billion JPY | -15.79% |
2021 Q3 | -4.52 Billion JPY | -8.21% |
2021 FY | -5.63 Billion JPY | -28.38% |
2021 Q1 | -3.54 Billion JPY | 19.21% |
2021 Q4 | -5.63 Billion JPY | -24.49% |
2021 Q2 | -4.18 Billion JPY | -17.95% |
2020 Q2 | -2.64 Billion JPY | -24.14% |
2020 FY | -4.38 Billion JPY | -133.83% |
2020 Q1 | -2.13 Billion JPY | -13.59% |
2020 Q4 | -4.38 Billion JPY | -40.05% |
2020 Q3 | -3.13 Billion JPY | -18.4% |
2019 Q3 | -1.68 Billion JPY | -101.13% |
2019 FY | -1.87 Billion JPY | -412.52% |
2019 Q1 | -35.61 Million JPY | 90.27% |
2019 Q2 | -839.06 Million JPY | -2255.99% |
2019 Q4 | -1.87 Billion JPY | -11.18% |
2018 Q2 | -604.76 Million JPY | -317.15% |
2018 FY | -366.08 Million JPY | 36.28% |
2018 Q4 | -366.08 Million JPY | -1517.56% |
2018 Q3 | 25.82 Million JPY | 104.27% |
2018 Q1 | -144.97 Million JPY | 74.77% |
2017 Q3 | -30.18 Million JPY | 0.0% |
2017 FY | -574.51 Million JPY | -505.06% |
2017 Q4 | -574.51 Million JPY | -1803.61% |
2016 FY | 141.83 Million JPY | 113.07% |
2015 FY | -1.08 Billion JPY | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 1.22 Billion JPY | 1008.539% |
Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 100.254% |
Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 102.855% |
Shionogi & Co., Ltd. | -346.47 Billion JPY | 96.788% |
Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | -212.268% |
Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 73.599% |
Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 81.895% |
Eisai Co., Ltd. | -97.93 Billion JPY | 88.635% |
Morishita Jintan Co., Ltd. | -667 Million JPY | -1568.605% |
Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 78.523% |
Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 66.193% |
Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 246.404% |
Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 243.036% |
Tsumura & Co. | 1.61 Billion JPY | 789.139% |
Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 74.797% |
Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 67.681% |
Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 106.444% |
Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 141.803% |
Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 138.402% |
KYORIN Holdings, Inc. | 7.06 Billion JPY | 257.643% |
Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | 1680.909% |
Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | 285.741% |
SymBio Pharmaceuticals Limited | -6.51 Billion JPY | -70.778% |
MedRx Co., Ltd | -1.72 Billion JPY | -547.07% |
Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | -27.685% |
Solasia Pharma K.K. | -668 Million JPY | -1566.107% |
Modalis Therapeutics Corporation | -1.47 Billion JPY | -656.633% |
ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | -53.448% |
Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 119.691% |
Cyfuse Biomedical K.K. | -2.96 Billion JPY | -275.902% |
Toho Holdings Co., Ltd. | -98.42 Billion JPY | 88.693% |